for people ages 18 years and up (full criteria)
study started
completion around
Principal Investigator
by Zev Wainberg (ucla)



This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Official Title

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies


Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin Lymphoma, Zimberelimab


You can join if…

Open to people ages 18 years and up

  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
  • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Adequate organ and marrow function

You CAN'T join if...

  • History of trauma or major surgery within 28 days prior to the first dose of study treatment.
  • Prior treatment with an anti-TIGIT antibody.
  • Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
  • Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
  • Discontinued prior immunotherapy for immune related adverse events with a high severity.

    NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


  • University of California, Los Angeles
    Los Angeles California 90095 United States
  • START South Texas Accelerated Research Therapeutics - Mountain Region
    West Valley City Utah 84119 United States

Lead Scientist at University of California Health

  • Zev Wainberg (ucla)
    HS Clinical Professor, Medicine. Authored (or co-authored) 153 research publications


in progress, not accepting new patients
Start Date
Completion Date
Arcus Biosciences, Inc.
Phase 1 research study
Study Type
About 94 people participating
Last Updated